What are the Global Initiative for Asthma (GINA) stepwise management recommendations for children with asthma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

GINA Guidelines for Childhood Asthma Management

Core Treatment Philosophy

All children with asthma should receive inhaled corticosteroid (ICS)-containing controller therapy rather than short-acting beta-agonist (SABA) alone, as SABA-only treatment increases the risk of severe exacerbations and asthma-related mortality. 1, 2, 3

The primary goals prioritize complete symptom abolition, normal lung function restoration, prevention of severe attacks, enabling normal growth, and eliminating school absences. 4


Age-Specific Assessment of Asthma Control

Children 0-4 Years

Well-controlled asthma is defined by ALL of the following: 5

  • Daytime symptoms ≤2 days/week
  • Nighttime awakenings ≤1 time/month
  • No interference with normal activity
  • SABA use ≤2 days/week
  • 0-1 exacerbations requiring oral corticosteroids per year

Not well-controlled when: 5

  • Daytime symptoms >2 days/week
  • Nighttime awakenings >1 time/month
  • Some activity limitation
  • SABA use >2 days/week
  • 2-3 exacerbations per year

Very poorly controlled when: 5

  • Symptoms throughout the day
  • Nighttime awakenings >1 time/week
  • Extreme activity limitation
  • SABA use several times per day
  • 3 exacerbations per year

Children 5-11 Years

Well-controlled asthma requires ALL of: 5

  • Daytime symptoms ≤2 days/week (not more than once each day)
  • Nighttime awakenings ≤1 time/month
  • No interference with normal activity
  • SABA use ≤2 days/week
  • FEV₁ or peak flow >80% predicted/personal best
  • FEV₁/FVC >80%
  • 0-1 exacerbations per year

Not well-controlled when: 5

  • Symptoms >2 days/week or multiple times on ≤2 days/week
  • Nighttime awakenings ≥2 times/month
  • Some activity limitation
  • SABA use >2 days/week
  • FEV₁ 60-80% predicted
  • FEV₁/FVC 75-80%

Very poorly controlled when: 5

  • Symptoms throughout the day
  • Nighttime awakenings ≥2 times/week
  • Extreme activity limitation
  • SABA use several times per day
  • FEV₁ <60% predicted
  • FEV₁/FVC <75%
  • ≥2 exacerbations per year

Stepwise Controller Therapy

Step 1: Mild Intermittent Asthma

For adults and adolescents (Track 1 preferred): As-needed low-dose ICS-formoterol combination is superior to SABA alone, reducing severe exacerbations by ≥60%. 1, 3

For children 5-11 years: Low-dose ICS is the preferred first-line controller therapy for persistent asthma. 6 Alternative options include leukotriene receptor antagonists (montelukast), cromolyn, or nedocromil, though these are less effective than ICS. 6

Step 2: Mild Persistent Asthma

Low-dose ICS delivered via metered-dose inhaler with spacer, dry powder inhaler, or nebulizer is the preferred therapy. 6

Step 3-4: Moderate Asthma

Step-up options when control is not achieved within 4-6 weeks: 6

  • Add long-acting beta-agonist (LABA) to low-dose ICS, OR
  • Increase ICS to medium-dose range, OR
  • Add leukotriene receptor antagonist to ICS

Step 5: Severe Asthma

High-dose ICS plus LABA combinations, with consideration for oral corticosteroids, add-on long-acting muscarinic antagonists, azithromycin, or biologic therapies. 7, 1


Device Selection by Age

Ages 0-4 years: MDI with spacer and face mask is the appropriate delivery device. 4

Ages 5+ years: MDI with spacer or dry powder inhaler. 4 For 7-year-olds specifically, an MDI with large-volume spacer is preferred because most children this age cannot achieve adequate coordination with an unmodified MDI. 6

Critical pitfall: Never use an unmodified MDI without a spacer because lung deposition is poor and systemic absorption increases. 6


Acute Severe Asthma Management

Recognition of Severity

Acute severe features: 4

  • Too breathless to talk or feed
  • Respirations >50 breaths/min
  • Pulse >140 beats/min
  • Peak flow <50% predicted or best

Life-threatening features: 4

  • Peak flow <33% predicted or best
  • Poor respiratory effort
  • Cyanosis, silent chest
  • Fatigue/exhaustion
  • Agitation or reduced consciousness

Immediate Treatment

Bronchodilator therapy: 6

  • Nebulized salbutamol 5 mg (or 2.5 mg for children under 2 years) via oxygen-driven nebulizer
  • Alternative: terbutaline 10 mg (half dose in very young children)

Corticosteroid therapy: 6, 4

  • Oral prednisolone 1-2 mg/kg daily (maximum 40 mg) is the preferred initial therapy for children who can tolerate oral medication.
  • Duration: 1-5 days until control is established, no tapering needed
  • Intravenous methylprednisolone (or hydrocortisone 200 mg every 6 hours) is reserved for children too ill to take oral medications or with life-threatening features

Corticosteroids must be administered immediately together with bronchodilator therapy; delaying steroid administration until after bronchodilator response provides no benefit. 6

Escalation for Life-Threatening Asthma

Intravenous aminophylline: 5 mg/kg over 20 minutes, followed by maintenance infusion of 1 mg/kg/hour. 6

Critical pitfall: Never omit the aminophylline loading dose without confirming theophylline use history, as giving a loading dose to a child already on oral theophyllines can cause toxicity. 6


Exercise-Induced Bronchoconstriction

Pretreat with albuterol 15 minutes before exercise to prevent exercise-induced bronchoconstriction. 6 Alternatively, a daily leukotriene receptor antagonist can be used as part of the controller regimen. 6

Encourage regular physical activity and implement a warm-up period before vigorous exercise to lessen severity. 6 Treat exercise-related bronchoconstriction rather than restricting activity. 6


Monitoring and Step-Down Criteria

At Every Visit

Verify inhaler technique at every visit; improper technique is the most common cause of apparent treatment failure. 6, 4

Document: 6

  • Days of school missed
  • Frequency of daytime and nighttime symptoms
  • Frequency of rescue medication use
  • Any activity limitation

Record height and weight velocities to monitor for potential growth suppression when high-dose ICS (>400 µg/day) are used. 6 Short-term reductions in tibial growth rate have been shown at doses greater than 400 µg/day, though low-dose regimens have minimal impact compared with the growth-delaying effect of uncontrolled asthma itself. 5, 6

Step-Down Criteria

Attempt step-down after benefits are sustained for 2-4 months, and reassess inhaler technique before stepping down. 6 Schedule regular follow-up every 3-6 months to reassess control and adjust therapy. 6


Self-Management and Education

Written Asthma Action Plan

All children with asthma should have a written asthma action plan developed with direct involvement of the child (when age-appropriate), addressing the child's concerns, preferences, and school schedule. 6, 3

The three essential elements are: 5

  1. Monitoring of symptoms, peak flow, and drug usage
  2. Taking prearranged action by the patient
  3. Written guidance for when to initiate or increase inhaled steroids, self-administer steroid tablets when peak flow falls below agreed levels or <60% of normal, and urgently seek medical attention when treatment is not working

School Medication Plan

Include a school medication administration plan to ensure the child has timely access to controller and rescue medication at school. 6


Treatment Outcomes and Goals

The outcome of successful management should be: 5

  • Minimal symptoms during the day and no waking at night
  • No missed playgroup, nursery, or school
  • Full participation in activities and sports
  • Relatively infrequent relief medication use

Common Pitfalls to Avoid

Antibiotics have no place in uncomplicated asthma management. 4 Antihistamines including ketotifen have proved disappointing in clinical practice. 4 Hyposensitization (immunotherapy) is not indicated in asthma management. 4

Routine home use of nebulizers should be avoided; an MDI with a large-volume spacer provides equivalent efficacy, is less costly, and reduces unnecessary nebulizer use. 6

References

Research

Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.

American journal of respiratory and critical care medicine, 2022

Research

Update on Asthma Management Guidelines.

Missouri medicine, 2024

Guideline

Childhood Asthma Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pediatric Asthma Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the recommendations for managing asthma according to GINA (Global Initiative for Asthma) guidelines?
What are the GINA (Global Initiative for Asthma) guidelines for managing asthma?
What is the recommended asthma action plan according to Global Initiative for Asthma (GINA) guidelines?
What are the recommendations for managing asthma according to the Global Initiative for Asthma (GINA) 2025 guidelines?
What are the GINA (Global Initiative for Asthma) guidelines for managing asthma?
What medication changes are recommended for a diabetic patient with hemoglobin A1c 5.6% who is taking semaglutide (Ozempic) 0.25 mg weekly and insulin aspart protamine/regular (Novolog) 70/30 5 mg?
What is a likely pain diagnosis for a 55‑year‑old man with three‑week low back pain radiating to the posterior right thigh and calf, right L5 sensory loss and weakness, a positive straight‑leg raise test, and magnetic resonance imaging (MRI) showing an L4‑L5 disc herniation?
What is the standard intrapleural streptokinase dosing regimen for an adult with a loculated parapneumonic empyema?
What does surgery for puborectalis dysfunction involve, how does it improve symptoms, and how soon can it be performed?
What are the 2026 American College of Obstetricians and Gynecologists (ACOG) guidelines for evaluating and managing endometriosis in a woman of reproductive age, including recommended diagnostic work‑up, first‑line medical therapy, second‑line options, fertility‑preserving surgery, and indications for definitive surgery?
For a man with puborectalis dysfunction refractory to 6–12 weeks of bio‑feedback, pelvic‑floor relaxation training, and pharmacologic therapy, what does the surgical repair involve, how does it improve bowel and sexual function, and how urgently should it be scheduled?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.